S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREAT...

por Telen, M, Saraf, S, Cruz, K, Idowu, M, Kalfa, T, Osunkwo, I, Hagar, R, Geib, J, Forsyth, S, Schroeder, P, Wu, E, Kelly, P, Brown, R
Publicado 2022

P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

por Saraf, S., Brown, R. C., Hagar, R. W., Idowu, M., Osunkwo, I., Kalfa, T. A., Kuypers, F. A., Geib, J., Schroeder, P., Wu, E., Kelly, P., Telen, M. J.
Publicado 2022